Luna AI

Ask Luna AI about markets, a ticker or your clients without leaving this page.

Opening the research desk…

Gilead Sciences, Inc. (GILD) stock price, chart and research

Gilead Sciences, Inc. (GILD) last traded at $167.58 at the close on November 16, 2026, down $0.50 (0.30%) on the day.

About Gilead Sciences, Inc.

Sector: Healthcare; industry: Drug Manufacturers - General; headquarters: United States; CEO: Mr. Daniel Patrick O'Day; 17,000 employees; listed since 1992-01-22.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck &…

Financials

Revenue over the last 12 months was $30.99 billion, net income $-3.86 billion, a profit margin of -12.5%. Revenue grew 6.5% from a year earlier.

Institutional owners of GILD (13F)

Tracked managers holding GILD in 13F filings for the quarter ending 2026-09-30:

ETFs that hold GILD

Research GILD with LunaTerminal

Market data via Fear & Greed (feargreedflow.com); 13F holdings from SEC filings. Market data can be delayed; check dates before relying on a figure. Answers are research, not financial advice.

Welcome back

Sign in to your research desk.

or

New here?

Portfolio report

Create an agent

Never include secrets in agent instructions.